Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HOLOGIC INCHOLX · Entity 12463 | Director | November 13, 2017 | November 15, 2017 |
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Director | May 22, 2019 | May 23, 2019 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | June 01, 2019 | June 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HOLOGIC INC
Report date November 13, 2017 · Filed November 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,302 |
Last balance in matching sequence
After 2017-11-14 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2017-11-13 · Exercise / conversion · Acquired 9,282 · Balance 33,092 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F2: Includes 3,260 shares subject to deferral pursuant to Issuer's Deferred Equity Plan. Row 2 · 2017-11-13 · Sale · Disposed 9,282 · Balance 23,810 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F2: Includes 3,260 shares subject to deferral pursuant to Issuer's Deferred Equity Plan. Row 3 · 2017-11-14 · Exercise / conversion · Acquired 3,492 · Balance 27,302 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F2: Includes 3,260 shares subject to deferral pursuant to Issuer's Deferred Equity Plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.82 · Expires 2018-01-01 | Direct | 3,492 |
Reported balance
After 2017-11-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-11-13 · Exercise / conversion · Disposed 9,282 · Balance 3,492 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F3: This option became fully vested on January 1, 2008 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.82 · Expires 2018-01-01 | Direct | 0 |
Reported balance
After 2017-11-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-11-14 · Exercise / conversion · Disposed 3,492 · Balance 0 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F3: This option became fully vested on January 1, 2008 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to an existing rule 10b5-1 trading plan.
F2: Includes 3,260 shares subject to deferral pursuant to Issuer's Deferred Equity Plan.
F3: This option became fully vested on January 1, 2008
THERMO FISHER SCIENTIFIC INC.
Report date May 22, 2019 · Filed May 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,706 |
Reported balance
After 2019-05-22 transaction · row 1
1 source rowRow 1 · 2019-05-22 · Grant · Acquired 718 · Balance 4,706 |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 3,638 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,638 F1: These shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust on May 6, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust on May 6, 2019.
VERTEX PHARMACEUTICALS INC / MA
Report date June 01, 2019 · Filed June 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $168.04 · Expires 2029-05-31 | Direct | 6,659 |
Reported balance
After 2019-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-01 · Grant · Acquired 6,659 · Balance 6,659 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2017 Filed Mar 7, 2017 22:01 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 1,044 | $32.82 | $34,258.86 |
DisclosureSEC source: 0001127602-17-010637 · form4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 22:01 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 9,256 | $0.00 Strike: $32.82 | $0.00 |
DisclosureSEC source: 0001127602-17-010637 · form4.xml · derivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,144 Underlying: Common Stock · 9,256 shares Expires 2017-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to an existing Rule 10b5-1 trading plan. F2 · derivative.exercise_date: This option became fully vested on 10/22/2007. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 22:01 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 9,256 | $40.82 | $377,829.92 |
DisclosureSEC source: 0001127602-17-010637 · form4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,252 F1 · kind: Shares exercised and sold pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 22:01 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 9,256 | $32.82 | $303,735.64 |
DisclosureSEC source: 0001127602-17-010637 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 877 | $0.00 Strike: $32.82 | $0.00 |
DisclosureSEC source: 0001127602-17-004347 · form4.xml · derivative · entry 5 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,400 Underlying: Common Stock · 877 shares Expires 2017-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option became fully vested on 10/22/2007. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 877 | $32.82 | $28,778.76 |
DisclosureSEC source: 0001127602-17-004347 · form4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 9,423 | $0.00 Strike: $32.82 | $0.00 |
DisclosureSEC source: 0001127602-17-004347 · form4.xml · derivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,277 Underlying: Common Stock · 9,423 shares Expires 2017-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option became fully vested on 10/22/2007. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 9,423 | $39.54 | $372,585.42 |
DisclosureSEC source: 0001127602-17-004347 · form4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,375 F1 · kind: Shares sold pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 9,423 | $32.82 | $309,215.75 |
DisclosureSEC source: 0001127602-17-004347 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 21:41 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 949 | $0.00 Strike: $32.82 | $0.00 |
DisclosureSEC source: 0001127602-17-001091 · form4.xml · derivative · entry 5 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,700 Underlying: Common Stock · 949 shares Expires 2017-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option became fully vested on 10/22/2007. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 21:41 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 949 | $32.82 | $31,141.44 |
DisclosureSEC source: 0001127602-17-001091 · form4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:41 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 9,351 | $0.00 Strike: $32.82 | $0.00 |
DisclosureSEC source: 0001127602-17-001091 · form4.xml · derivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,649 Underlying: Common Stock · 9,351 shares Expires 2017-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option became fully vested on 10/22/2007. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:41 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 9,351 | $40.00 | $374,040.00 |
DisclosureSEC source: 0001127602-17-001091 · form4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,426 F1 · kind: Shares sold pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:41 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 9,351 | $32.82 | $306,853.07 |
DisclosureSEC source: 0001127602-17-001091 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2016 Filed Oct 12, 2016 20:53 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,764 | $0.00 Strike: $32.82 | $0.00 |
DisclosureSEC source: 0001127602-16-064729 · form4.xml · derivative · entry 5 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 1,764 shares Expires 2017-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option became fully vested on 10/22/2007. Read SEC document |
| October 11, 2016 Filed Oct 12, 2016 20:53 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 1,764 | $32.82 | $57,885.66 |
DisclosureSEC source: 0001127602-16-064729 · form4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 20:53 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 18,236 | $0.00 Strike: $32.82 | $0.00 |
DisclosureSEC source: 0001127602-16-064729 · form4.xml · derivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,764 Underlying: Common Stock · 18,236 shares Expires 2017-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option became fully vested on 10/22/2007. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 20:53 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 18,236 | $39.88 | $727,269.92 |
DisclosureSEC source: 0001127602-16-064729 · form4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,662 F1 · shares: Shares sold pursuant to an existing Rule 10b5-a trading plan. F2 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $39.86 to $39.89 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 20:53 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 18,236 | $32.82 | $598,414.34 |
DisclosureSEC source: 0001127602-16-064729 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 7,073 | $0.00 Strike: $93.51 | $0.00 |
DisclosureSEC source: 0001209191-16-125724 · doc4.xml · derivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,073 Underlying: Common Stock · 7,073 shares Expires 2026-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,941 | $0.01 | $29.41 |
DisclosureSEC source: 0001209191-16-125724 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,206 F1 · shares: Restricted stock unit award that vests on the first anniversary of the grant date. Read SEC document |
| May 18, 2016 Filed May 20, 2016 20:39 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-052941 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,651 Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-15-083423 · doc4.xml · derivative · entry 6 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $131.38 | $13,138.00 |
DisclosureSEC source: 0001209191-15-083423 · doc4.xml · nonDerivative · entry 5 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,400 | $130.68 | $705,672.00 |
DisclosureSEC source: 0001209191-15-083423 · doc4.xml · nonDerivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,365 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $130.68 (range $130.26 to $131.25). Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,711 | $129.77 | $1,389,966.47 |
DisclosureSEC source: 0001209191-15-083423 · doc4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,765 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $129.77 (range $129.25 to $130.24). Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,289 | $128.78 | $809,897.42 |
DisclosureSEC source: 0001209191-15-083423 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,476 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $128.78 (range $128.25 to $129.23). F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 22,500 | $59.55 | $1,339,875.00 |
DisclosureSEC source: 0001209191-15-083423 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $53.85 | $0.00 |
DisclosureSEC source: 0001209191-15-078404 · doc4.xml · derivative · entry 7 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,100 | $127.62 | $268,002.00 |
DisclosureSEC source: 0001209191-15-078404 · doc4.xml · nonDerivative · entry 6 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $127.62 (range $127.46 to $127.85). Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,708 | $126.91 | $851,312.28 |
DisclosureSEC source: 0001209191-15-078404 · doc4.xml · nonDerivative · entry 5 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $126.91 (range $126.44 to $127.43). Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,592 | $125.98 | $1,208,400.16 |
DisclosureSEC source: 0001209191-15-078404 · doc4.xml · nonDerivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,073 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $125.98 (range $125.44 to $126.43). Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $125.09 | $87,563.00 |
DisclosureSEC source: 0001209191-15-078404 · doc4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,665 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $125.09 (range $124.44 to $125.38). Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $123.66 | $111,294.00 |
DisclosureSEC source: 0001209191-15-078404 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,365 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $123.66 (range $123.40 to $124.27). Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $53.85 | $1,077,000.00 |
DisclosureSEC source: 0001209191-15-078404 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2015 Filed Oct 6, 2015 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0001209191-15-074366 · doc4.xml · derivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| October 02, 2015 Filed Oct 6, 2015 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20,000 | $110.00 | $2,200,000.00 |
DisclosureSEC source: 0001209191-15-074366 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · shares: Transaction made pursuant to M. Ullian's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 02, 2015 Filed Oct 6, 2015 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $34.24 | $684,800.00 |
DisclosureSEC source: 0001209191-15-074366 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2015 Filed Jul 30, 2015 20:45 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GiftCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-023769 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,651 Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $127.54 | $0.00 |
DisclosureSEC source: 0001209191-15-049649 · doc4.xml · derivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2025-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 20, 2015 Filed May 22, 2015 17:58 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 1,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-018230 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,051 Read SEC document |
| January 02, 2015 Filed Jan 6, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0001209191-15-002257 · doc4.xml · derivative · entry 6 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2016-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 02, 2015 Filed Jan 6, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $123.57 | $12,357.00 |
DisclosureSEC source: 0001209191-15-002257 · doc4.xml · nonDerivative · entry 5 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 02, 2015 Filed Jan 6, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,100 | $122.96 | $381,176.00 |
DisclosureSEC source: 0001209191-15-002257 · doc4.xml · nonDerivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,365 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $122.96 (range $122.54 to $123.41). Read SEC document |
| January 02, 2015 Filed Jan 6, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,700 | $122.15 | $207,655.00 |
DisclosureSEC source: 0001209191-15-002257 · doc4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,465 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $122.15 (range $121.53 to $122.48). F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2015 Filed Jan 6, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $118.91 | $11,891.00 |
DisclosureSEC source: 0001209191-15-002257 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,165 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 02, 2015 Filed Jan 6, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $34.32 | $171,600.00 |
DisclosureSEC source: 0001209191-15-002257 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0001209191-14-061668 · doc4.xml · derivative · entry 8 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2016-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $111.57 | $11,157.00 |
DisclosureSEC source: 0001209191-14-061668 · doc4.xml · nonDerivative · entry 7 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $110.45 | $11,045.00 |
DisclosureSEC source: 0001209191-14-061668 · doc4.xml · nonDerivative · entry 6 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,365 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.